Acurx Pharmaceuticals, Inc. (ACXP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Acurx Pharmaceuticals, Inc. (ACXP) closed at USD 1.15 on 2026-10-14, a change of -81.7 % over the past year, with a market capitalization of USD 6.5M.

Acurx Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Acurx Pharmaceuticals, Inc. key figures

Previous close

USD 1.15 (2026-10-14)

1-year change

-81.7 %

Market cap

USD 6.5M

Enterprise value

USD -4.49M

P/E ratio (trailing)

-0.45

P/E ratio (forward)

-0.67

EPS (trailing)

-2.63

EPS (forward)

-1.75

PEG ratio

n/a

Price to book

0.67

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.21

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Acurx Pharmaceuticals, Inc. and compare it with other stocks.